Pesky bush ticks could be key to saving lives in world-first HRI research
HRI is on the cusp of developing a drug to save people from deadly strokes using a common Australian bush tick.
Cardiometabolic Disease Group publishes review on heart failure models
The Cardiometabolic Disease Group at HRI has published a much-needed review on models of heart failure with preserved ejection fraction (HFpEF).
PhD student Paraskevi Morris speaks at CSANZ
PhD student Paraskevi (Evi) Morris recently spoke at the 69th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ) 2021.
Making cardiovascular medical devices safer
Dr Anna Waterhouse is investigating how vital medical devices, such as those used in heart surgery, can be made safer for patients.
HRI investigates link between AstraZeneca COVID-19 vaccine and blood clots
In an Australian first, a pilot study will seek to find biomarkers for blood clot risks in patients who have been given the AstraZeneca COVID-19 vaccine.
Global media interest in HRI’s world-first stroke drug trial
HRI researchers led by Professor Shaun Jackson have developed an anti-clotting drug that offers new hope to stroke sufferers.
Groundbreaking world-first trial offers new hope to stroke sufferers
HRI's top stroke experts are leading a world-first trial which could be a game-changer when it comes to debilitating strokes.
Dr Jessica Maclean awarded THANZ grant
Dr Jessica Maclean has been awarded a THANZ Scientific & Education Trust Grant to further investigate novel antiplatelet strategies to enhance stroke treatment.
Dr Ashish Misra awarded second Perpetual IMPACT grant
Dr Ashish Misra was recently awarded his second Perpetual IMPACT grant. Dr Misra’s research focuses on improved understanding and potential treatment of atherosclerosis.